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E-mail: johanna.magga@oulu.fiActivin A and myostatin, members of the transforming growth
factor (TGF)-b superfamily of secreted factors, are potent nega-
tive regulators of muscle growth, but their contribution to
myocardial ischemia-reperfusion (IR) injury is not known.
The aim of this study was to investigate if activin 2B (ACVR2B)
receptor ligands contribute to myocardial IR injury. Mice were
treated with soluble ACVR2B decoy receptor (ACVR2B-Fc)
and subjected to myocardial ischemia followed by reperfusion
for 6 or 24 h. Systemic blockade of ACVR2B ligands by
ACVR2B-Fc was protective against cardiac IR injury, as evi-
denced by reduced infarcted area, apoptosis, and autophagy
and better preserved LV systolic function following IR.
ACVR2B-Fc modified cardiac metabolism, LV mitochondrial
respiration, as well as cardiac phenotype toward physiological
hypertrophy. Similar to its protective role in IR injury in vivo,
ACVR2B-Fc antagonized SMAD2 signaling and cell death in
cardiomyocytes that were subjected to hypoxic stress. ACVR2B
ligand myostatin was found to exacerbate hypoxic stress. In
addition to acute cardioprotection in ischemia, ACVR2B-Fc
provided beneficial effects on cardiac function in prolonged
cardiac stress in cardiotoxicity model. By blocking myostatin,
ACVR2B-Fc potentially reduces cardiomyocyte death and
modifies cardiomyocyte metabolism for hypoxic conditions
to protect the heart from IR injury.
INTRODUCTION
Development of the heart is guided by secreted morphogens
including members of the transforming growth factor (TGF)-b super-
family.1 In addition to their regulatory function in organogenesis, the
TGF-b family of growth factors, including activins, bone morphoge-
netic proteins (BMPs), and growth differentiation factors (GDF), are
known to regulate cardiac physiology and pathophysiology in the
adult heart. These factors signal through type I and type II receptors,600 Molecular Therapy Vol. 27 No 3 March 2019 ª 2019 The Author(s)
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Activins and GDFs bind to activin receptor IIA and B (ACVR2A
and ACVR2B),2,3 which in turn activate type I receptors such as
activin receptor-like kinases (ALK) ALK4 and ALK5, activating
downstream molecule SMAD2/3.4,5 SMADSs regulate a number of
myogenic genes, such as myoD, myogenin, and Myf5, that are
involved in cellular hypertrophy, proliferation, or differentiation.6
In addition to signaling via SMAD proteins, GDFs also signal through
noncanonical pathways to regulate cardiomyocyte growth7 by upre-
gulation of atrophy-related atrogenes or autophagy genes, resulting
in proteasome-dependent muscle protein degradation. Noncanonical
ACVR2B pathways have also been shown to regulate MAP kinases.5
Activin A is upregulated in the heart after myocardial infarction (MI)
or ischemia-reperfusion (IR) injury.8,9 Serum levels of activin A in-
crease inMI, and its expression levels correlate with creatinine kinase,
as a measure of infarct size.10 In an experimental model, cardiac
myostatin (also known as GDF8) is upregulated immediately after
MI.11 Follistatin, an endogenous antagonist to myostatin and
activin, has been shown to reduce IR injury in mice.9 When utilizing
myostatin-deficient mice, it was recently shown that the absence of
myostatin improves cardiac function after MI.12 In contrast to reports
suggesting activin A as a culprit in IR injury, overexpression of
activin A has also been shown to be protective against cardiomyocyte
death, and its antagonism by Fstl3 exacerbates IR injury.8 Myocardial
stretch was recently shown to induce activin A in a genome-wide
time series study of gene expression changes in stretched neonatal.
vecommons.org/licenses/by/4.0/).
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Fstl3 were briefly upregulated after induction of stretch and substan-
tially before activation of activin A.13 It is not understood how acti-
vins and GDFs contribute to cardiomyocyte viability and function
in myocardial ischemia.
Reperfusion by percutaneous catheter angioplasty is the main treat-
ment for MI. While necessary to salvage ischemic myocardium, re-
perfusion itself may impair microvascular function and paradoxically
trigger further injury.14 Cardioprotection from reperfusion injury has
been experimentally studied by local ischemic pre- and post-condi-
tioning procedures as well as by remote ischemic preconditioning.
This, achieved by short repetitive IR periods, is thought to activate
pathways targeting mitochondria and thus reduce the formation of
reactive oxygen species as well as inhibit the opening of mitochondrial
permeability transition pore (mPTP).14
In addition, various growth factors and pharmacological agents have
been explored for reducing reperfusion injury. Atrial natriuretic pep-
tide (ANP), glucose-insulin-potassium therapy, glucagon like peptide-
1 (GLP-1) analog exenatide or b-blocker metoprolol can potentially
induce cardioprotection by inducing cGMP/PKG signaling, promot-
ing glucosemetabolism and utilization or reducingmyocardial oxygen
consumption, respectively.15 Furthermore, agents targeting mito-
chondria by enhancing mitochondrial energetics or inhibiting
mPTP opening have shown efficacy in experimental models of IR
injury. However, many of these have not (yet) been shown to be
cardioprotective in clinical studies.16 Some of them have failed in clin-
ical studies, possibly due to timing or dosing of the agent or heterolo-
gous patient population selected for the study.
Despite current invasive strategies to treat MI, novel cardioprotective
agents are still needed to attenuate IR injury in order to prevent
ischemia-induced heart failure and improve prognosis. In this study,
we show that treating mice with ACVR2B-Fc decoy receptor pro-
tects the myocardium from IR injury. In earlier characterization,
ACVR2B-Fc has been shown to bind endogenous ligands myostatin
(GDF8), GDF11, and activin A with high affinity17 and inhibit phys-
iological responses of ACVR2B ligands.18–20 Our results indicate that
ACVR2B ligand myostatin activates SMAD2/3 and contributes to IR
injury. This is salvageable by pharmacological inhibitor ACVR2B-Fc.
RESULTS
SystemicBlockade of ACVR2BLigandsReduces Ischemic Injury
and Restores Cardiac Function in an Experimental Model of
Ischemia Reperfusion
To study the contribution of ACVR2B signaling to ischemic myocar-
dial injury, we treated mice with a soluble decoy receptor of ACVR2B
24 h before ischemia (“ACVR2B-Fc pretreatment”) to block the func-
tion of ACVR2B ligands and subjected the mice to transient IR by
ligation of LAD. 30 min of ischemia followed by 6 h or 24 h of reper-
fusion resulted in left ventricular (LV) cell death and deteriorated
cardiac function 24 h after IR. When analyzed with triphenyltetrazo-
lium chloride (TTC) stain, ACVR2B-Fc reduced infarcted area in LV(p < 0.01; Figure 1A). This was accompanied by reduced, although not
statistically significant, release of cardiac troponin I into plasma (p =
0.09; Figure 1B). Treatment with ACVR2B-Fc preserved cardiac func-
tion after IR as measured by echocardiography, but not if the treat-
ment was initiated at reperfusion (“ACVR2B-Fc at reperfusion”).
Ejection fraction was significantly better preserved with ACVR2B-
Fc (p < 0.01; Figure 1C; see also Figure S1). In addition, fractional
shortening and endocardial fractional area change were improved
after ACVR2B-Fc treatment in comparison to vehicle-treated IR
mice (p < 0.01; Table S2). Administration of ACVR2B-Fc reduced
LV diameter (p < 0.01) and increased LV posterior wall thickness
in IR mice (p < 0.05, Figures 1C and 1D; see also Table S2). This
was associated with increased cardiomyocyte cross-sectional area
(p < 0.05; Figure 1D), slightly increased LV mass (Figure 1C), and
total heart weight (146 ± 18 mg in vehicle-treated and 158 ± 19 mg
in ACVR2B-Fc-treated IRmice). A similar effect on cardiac hypertro-
phy was detected in healthy mice treated with sACVR2B as cardio-
myocyte cross-sectional area was increased (Figure S2). The same
mice also showed a non-significant increase in skeletal muscle hyper-
trophy (Figure S2). Cardiac hypertrophy was accompanied by tran-
sient phosphorylation and inactivation of GSK3b (Figure S2), which
promotes LV hypertrophy and enhances resistance of cardiomyocytes
to oxidative stress.21
SystemicBlockadeof ACVR2BLigandsReduces Ischemic Injury
and Suppresses SMAD2, Apoptotic Stress-Induced Signaling
Pathways, and Autophagy
To study the mechanisms of ACVR2B-Fc-mediated protection, we
performed further analysis for apoptotic pathways. A TUNEL stain
was performed 6 h after reperfusion and showed that ACVR2B-Fc
reduced apoptosis in LV (p < 0.05; Figure 2A; Figure S2). This was
accompanied by reduced expression of Bcl-2 family pro-apoptotic
protein Bim (p < 0.05; Figure 2B). IR-induced activation of SMAD2
protein in the infarcted and peri-infarcted zone was inhibited by
ACVR2B-Fc (p < 0.001; Figure 2C). In addition, ACVR2B-Fc reduced
IR-induced phosphorylation of JNK (p < 0.01; Figure 2C) while hav-
ing no effect on activation of ERK1/2 or p38. Furthermore, ACVR2B-
Fc did not affect activation of phosphatidylinositol 3-kinase (PI3K)/
Akt pathway (Figure 2C). ACVR2B signaling is known to promote
autophagy, leading to protein degradation. Systemic blockade of
ACVR2B ligands by ACVR2B-Fc led to reduction of autophagosomal
LC3II form and decreased autophagosomal/cytoplasmic/LC3II/LC3I
ratio (p < 0.05; Figure 2D) indicating reduced autophagy in the heart.
Since ACVR2B ligand GDF11 negatively regulates erythrocyte matu-
ration7 and activin A associates with inflammatory processes,22 we
additionally studied whether erythropoiesis, leukocyte infiltration,
or inflammatory response after IR are affected by ACVR2B-Fc. Blood
cell count performed 24 h after IR did not reveal any difference in
red blood cell count between ACVR2B-Fc and vehicle-treated mice
(Table S3), and leukocyte counts were also not affected. We then
determined if ACVR2B-Fc affects granulocyte infiltration after IR.
As analyzed from neutrophil stain, ACVR2B-Fc did not affect neutro-
phil infiltration into LV (Figure S3). In addition, ACVR2B-Fc did notMolecular Therapy Vol. 27 No 3 March 2019 601
Figure 1. ACVR2B-Fc Reduces Ischemia-Reperfusion Injury and Restores Cardiac Function
Mice were treated with vehicle (white columns) or with a soluble decoy receptor ACVR2B-Fc at reperfusion (ACVR2B-Fc at reperfusion, gray columns) or 24 h prior to/at
reperfusion (ACVR2B-Fc pretreatment, black columns). IR was achieved by transient ligation of left anterior descending (LAD) coronary artery for 30 min, followed by re-
perfusion for 24 h. (A) ACVR2B-Fc reduced infarcted area as determined with triphenyltetrazolium chloride (TTC stain). n = 7, 8. (B) ACVR2B-Fc reduced cardiac troponin I
release into plasma (p = 0.09). n = 8, 9. (C) As determined with echocardiography, ACVR2B-Fc preserved cardiac function after IR observed as preserved ejection fraction.
ACVR2B-Fc also reduced left ventricular diameter in diastole (LVID;d) and increased LV posterior wall thickness (LVPW;d) in IR mice with slightly increased total LV mass.
Sham values are shown as a dotted line. n = 19, 9, 18. Full echo data in Table S2. (D) ACVR2B-Fc increased cardiomyocyte cross-sectional area. Masson trichrome stained
heart section cut horizontally (above) and representative pictures of single cross-sectional cardiomyocytes circled for cardiomyocyte area analysis (below). Sham values are
shown as a dotted line. Scale bar, 50 mm. n = 10, 9, 8. Data are presented as mean ± SD. *p < 0.05, **p < 0.01.
Molecular Therapysignificantly reduce the expression of pro-inflammatory cytokines or
chemokines in LV (Figure S3). Consequently, cardioprotection by
ACVR2B-Fc was not explained by enhanced erythropoiesis or
reduced inflammatory response.
ACVR2B-Fc Inhibits Myostatin-Mediated Activation of SMAD2/3
Pathway in Cardiomyocytes
First, we investigated whether ACVR2B-Fc induces cardioprotection
directly to cardiomyocytes during hypoxia. Similar to cardioprotec-
tion in vivo, ACVR2B-Fc provided protection to adult cardiomyo-
cytes from hypoxia-induced cell death (p < 0.01; Figure 3A). We
then wanted to decipher which ACVR2B ligands could contribute
to ischemic injury in adult cardiomyocytes. Myostatin and, to smaller
extent, activin A, exacerbated ischemic injury in adult cardiomyo-
cytes, while GDF11, activin B, or GDF15 had no effect (Figure 3B).
To study the ACVR2B-Fc-mediated SMAD signaling in cellular level,
we transfected neonatal cardiomyocytes with CAGA-luc SMAD2/3
reporter or BRE-luc SMAD1/5/8 reporter and performed luciferase
promoter assay to detect respective SMAD activity. To validate the
model, we stimulated neonatal cardiomyocytes with factors expected
to activate SMADs and to confirm that this signaling occurs in cardi-
omyocytes. As expected, myostatin, GDF11, activin A, activin B, and
TGF-b induced SMAD2/3-dependent promoter activity (Figure 3C).602 Molecular Therapy Vol. 27 No 3 March 2019GDF15, which signals via GFRAL receptor (not via ACVR2B recep-
tor), was used here as a negative control and did not induce
SMAD2/3 activity (Figure 3C). None of these ligands stimulated
BRE-luc, which was used to assess SMAD1/5/8 activity, and which
was activated by BMP4 (Figure S4). To confirm the efficacy of
ACVR2B-Fc in reduction of SMAD activation, primary neonatal
cardiomyocytes were subjected to hypoxia. As seen in Figure 3D, hyp-
oxia induced SMAD2/3-dependent promoter activity in neonatal
cardiomyocytes, while SMAD1/5/8 signaling was not activated.
Administration of ACVR2B-Fc, which reduced SMAD2 signaling
in vivo, reduced hypoxia-induced SMAD2/3-dependent promoter
activity (p < 0.01; Figure 3D).
We then analyzed the time course of expression of ACVR2B ligands
in the heart 6 h and 24 h after IR in vivo. qPCR analysis showed that
levels of myostatin (Mstn) and activin A (Inhba) were upregulated in
the infarct and/or peri-infarct zones while activin B (Inhbb) was not
affected (Figure 3E; Figure S4). This was accompanied by correspond-
ing changes in protein levels measured from LV by western blotting
(Figure 3F). Similarly, immunostaining of LV sections showed
increased activin A levels in the infarct and peri-infarct zones (Fig-
ure S4), localization of activin A in cardiomyocytes and, to a smaller
extent, in endothelial cells. Interestingly, activin B was mainly de-
tected in the infarct and peri-infarct zones in leukocytes, apparently
Figure 2. ACVR2B-Fc Reduces Activation of SMAD2, Apoptotic Stress-Induced Signaling Pathways, and Autophagy
Mice were treated with vehicle (white columns), with soluble decoy receptor ACVR2B-Fc only at reperfusion (gray columns), or with pretreatment of ACVR2B-Fc 24 h prior
to/at reperfusion (black columns). IR was achieved by transient ligation of left anterior descending (LAD) coronary artery for 30 min, followed by reperfusion for 6 h. (A)
ACVR2B-Fc reduced apoptosis. n = 5, 6, 6. (B) ACVR2B-Fc reduced expression of Bcl-2 family pro-apoptotic protein Bim. n = 5, 6, 6. (C) ACVR2B-Fc inhibited IR-induced
activation of SMAD2 protein in infarcted and peri-infarcted zone. ACVR2B-Fc also reduced IR-induced phosphorylation of JNK but had no effect on activation of p38,
ERK1/2, or Akt. n = 5, 6, 6. (D) ACVR2B-Fc reduced autophagosomal lipidated LC3II form and decreased autophagosomal/cytoplasmic/LC3II/LC3I ratio in LV as analyzed
24 h after reperfusion. n = 7, 8, 8. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
www.moleculartherapy.orgneutrophils, and was only found in cardiomyocytes 24 h after IR and
to a smaller extent than observed in the leukocytes. Myostatin levels
were already high at basal levels in sham hearts, and there was aminor
increase inmyostatin levels in infarct and peri-infarct zones at 6 h and
24 h after IR; myostatin expression was only localized to cardiomyo-
cytes (Figure S4).
Different from other ACVR2B ligands, Gdf11 was downregulated in
the early phase after IR but upregulated at 24 h (Figure 3G). No
change was observed in Tgfb expression following IR (Figure 3G).
When determining the expression levels of activin receptors, both
Acvr2B and Acvr2A receptors were downregulated in the peri-infarct
zone at 6 h after IR (Figure 3G). After 24 h, Acvr2B downregulation
sustained, while Acvr2A expression was elevated back to basal level.
Expression of Bmpr2, the receptor for BMP ligands, was not affected
(1 ± 0.17 in sham versus 0.93 ± 0.29 at IR 24 h). Finally, as confirmed
in neonatal cardiomyocytes, myostatin and activin A were upregu-
lated after hypoxia, while the expression of activin B was not changed
(Figure 3H). In summary, our data suggest myostatin and activin
A are elevated shortly after hypoxia and they activate ACVR2B in
cardiomyocytes, leading to increased SMAD2/3 activity. Myostatin
exacerbated hypoxic injury, which was associated with increased car-
diomyocyte death. Similar to cardioprotective effects of ACVR2B-Fc
observed in IR model in vivo, ACVR2B-Fc directly protected cardio-
myocytes in vitro.Systemic Blockade of ACVR2B Ligands Optimizes Cardiac
Metabolism to Hypoxic Conditions in the IR Model
We next studied the effect of ACVR2B-Fc on cardiac metabolism
following cardiac IR injury. We found that administration of
ACVR2B-Fc upregulated the expression of peroxisome proliferator-
activated receptor gamma coactivator 1 (Ppargc1a) isoforms
Pgc1a1 and Pgc1a4 (p < 0.05; Figure 4A), which are central regulators
of mitochondrial energy production. ACVR2B-Fc did not affect the
gene expression of oxidative phosphorylation enzyme cytochrome
C (Cycs) or glycolytic enzymes Pgam1 or Gapdh (Figure 4A). Howev-
er, improvement of energy metabolism by ACVR2B-Fc was associ-
ated with an increased expression of glycolytic phosphofructokinase
enzyme Pfkm and upregulation of insulin-regulated glucose trans-
porter Glut4 (p < 0.05; Figure 4A), suggesting an increased glucose
uptake and glycolysis. ACVR2B-Fc increased phosphorylation of
acetyl-CoA carboxylase, reducing its enzymatic activity in the fatty
acid synthesis pathway in healthy hearts (Figure S4). However,
ACVR2B-Fc did not reduce fatty acid synthesis in IR hearts
(Figure S4).
Administration of ACVR2B-Fc had no effect on acute IR-injury-
induced increase in expression of atrial or B-type natriuretic peptides
ANP (Nppa) (IR vehicle 3.2 ± 1.4 versus IR ACVR2B-Fc pretreatment
2.6 ± 1.1, p = 0.52) or BNP (Nppb) (IR vehicle 1.9 ± 0.8 versus IR
ACVR2B-Fc pretreatment 1.5 ± 0.6, p = 0.44) but affected theMolecular Therapy Vol. 27 No 3 March 2019 603
Figure 3. ACVR2B-Fc Protects Cardiomyocytes in Hypoxic Conditions and Inhibits Myostatin-Activated SMAD2/3 Pathway in Cardiomyocytes
(A) ACVR2B-Fc protects adult rat ventricular cardiomyocytes (ARVM) from hypoxia-induced cell death as measured with adenylate kinase release. n = 6. (B) ACVR2B ligand
myostatin reduces cell survival in hypoxia. Cell toxicity was assessed with adenylate kinase release, and cell viability was determined with resazurin assay measuring cell
metabolism. The hypoxia value is shown as a dotted line. n = 6. (C) Neonatal rat ventricular cardiomyocytes (NRVM) were transfected with CAGA-luc SMAD2/3 reporter, and
subsequently luciferase reporter activity was analyzed after treatment with ACVR2B ligands, TGF-b, or the GFRAL receptor ligand GDF15. n = 12. (D) Hypoxia induced
SMAD2/3-dependent promoter activity in NRVM while SMAD1/5/8 signaling was not activated. ACVR2B-Fc reduced hypoxia-induced SMAD2/3-dependent promoter
activity in NRVM. n = 6. (E) Expression of ACVR2B ligands myostatin (Mstn), activin A (Inhba), and activin B (Inhbb) in infarct and peri-infarct zone in LV 6 and 24 h after IR,
analyzed by qPCR. The sham value is shown as a dotted line. n = 5–6 (6 h IR); n = 8–9 (24 h IR). (F) The levels of ACVR2B ligands in LV, analyzed by western blotting. n = 5 (6 h
IR); n = 9 (24 h IR). (G) Expression of ACVR2B ligandGdf11 and Tgfb, as a control, and ACVR2B receptorsAcvr2B and Acvr2A in LV 6 and 24 h after IR, analyzed by qPCR. n =
5–6 (6 h IR); n = 8–9 (24 h IR). (H) As confirmed in NRVM, myostatin and activin A were upregulated after hypoxia. The normoxia value is shown as dotted line. n = 6. Data are
presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
Molecular Therapycomposition of cardiomyocyte myosin fibers. ACVR2B-Fc slightly,
although not significantly, decreased expression of myosin heavy
chain (MHC)-b (Myh7) slow twitch isoform while increasing expres-
sion ofMHC-a (Myh6) fast twitchmyosin fibers (p < 0.01; Figure 4B).
This was accompanied with increased expression of Cited4 (p < 0.05;
Figure 4B), a transcription factor involved in physiological
hypertrophy.23,24
To confirm the effect of ACVR2B-Fc on cardiomyocyte meta-
bolism, we performed a bioenergetic assay in cardiomyocytes
in vitro. Adult LV cardiomyocytes obtained from mice treated
with ACVR2B-Fc for 48 h showed reduced metabolic activity
with attenuated oxygen consumption when subjected to hypoxic
conditions in vitro (Figure 4C). Cardiomyocytes of ACVR2B-Fc-
treated mice showed both reduced maximal respiration and reduced
spare respiratory capacity compared to cardiomyocytes from
vehicle-treated mice (Figure 4D). We did not detect pronounced in-
duction of glycolysis (Figure 4E), and upregulation of mitochon-
drial glycolytic enzymes detected by qPCR may thus represent a
compensatory increase of metabolic enzymes after myocardial
hibernation.604 Molecular Therapy Vol. 27 No 3 March 2019Systemic Blockade of ACVR2B Ligands during Prolonged
Cardiac Stress Improves LV Function
To determine the long-term effects of ACVR2B-Fc-inducedmetabolic
changes on cardiac function, we measured mitochondrial respiration
in LV ex vivo. We treated mice with anthracycline antitumor agent
doxorubicin, which induces cardiotoxicity by increased oxidative
stress, alterations in ion homeostasis, inhibition of protein synthesis,
and eventually, mitochondrial failure.25 To study if ACVR2B-Fc could
protect the heart from doxorubicin-induced deterioration of cardiac
metabolic function, wemeasured oxidative function from LV utilizing
a high-resolution respirometer.We found that ACVR2B-Fc treatment
improved cardiac respiration in doxorubin-stressed hearts (Fig-
ure 5A). ACVR2B-Fc also slightly, but significantly, improved citrate
synthase activity (Figure 5B). This result may be independent of mito-
chondrial number, as doxorubicin or ACVR2B-Fc had no significant
effect on the mitochondrial respiratory chain (OXPHOS and cyto-
chrome C) protein contents (data not shown). Furthermore, utilizing
echocardiography, we assessed the effect of ACVR2B-Fc treatment
on cardiac function after cumulative doxorubicin-induced toxicity.
We found that treatment of mice with ACVR2B-Fc inhibited
the doxorubicin-induced deterioration of cardiac systolic function
Figure 4. ACVR2B-Fc Optimizes Metabolism to
Hypoxic Conditions in IR
Expression of genes were analyzed with qPCR 24 h after
IR from the peri-infarct zone. (A) ACVR2B-Fc upregulated
expression of peroxisome proliferator-activated receptor
gamma coactivator 1 isoforms PGC1a1 and PGC1a4
and did not affect the gene expression of oxidative
phosphorylation enzyme cytochrome C (Cycs), but it
increased expression of glycolytic phosphofructokinase
enzyme Pfkm and insulin-regulated glucose uptake
transporter Glut4. Vehicle-treated IR mouse values are
shown as dotted line. n = 9, 8. (B) ACVR2B-Fc upregu-
lated expression of MHC-a (Myh6) fast twitch myosin
fibers and Cited4, a transcription factor involved in
physiological hypertrophy. Vehicle-treated IR mouse
values are shown as a dotted line. n = 9, 8. Data are
presented as mean ± SD. *p < 0.05, **p < 0.01. (C)
ACVR2B-Fc reduced metabolism in adult mouse car-
diomyocytes after 4 h hypoxia followed by 1 h reperfusion
as determined by oxygen consumption rate (OCR) with
bioenergetic mito stress assay. (D) The values for basal
and maximal respiration and spare respiratory capacity
were calculated from OCR graphs. n = 13, 11 (normoxia);
n = 6, 5 (hypoxia). (E) Bioenergetic phenotype profile
visualized from mito stress assay data. Basal phenotype
from the beginning of the experiment versus stressed
phenotype (after oligomycin and FCCP injections) in cells
subjected to normoxia or hypoxia. n = 13, 11 (normoxia);
n = 6, 5 (hypoxia).
www.moleculartherapy.org(Figure 5C; see also Table S4). qPCR analysis of cardiac samples
showed that administration of ACVR2B-Fc reduced doxorubicin-
induced upregulation of natriuretic peptides ANP (Nppa) and BNP
(Nppb) (Figure 5D), indicators of pathological cardiac remodeling.26
DISCUSSION
ACVR2B-FcContributes to Ischemia Protection byRegulation of
Myostatin Signaling in Cardiomyocytes
Repetitive ischemic preconditioning downregulates expression of
myostatin in both ischemic and remote myocardium. This suggestsModownregulation of myostatin is associated
with preconditioning-induced cardioprotection
in reperfusion injury.27 Here, we demonstrate
that systemic blockade of ACVR2B ligands pro-
tects the heart from IR injury by reducing hyp-
oxia-activated myostatin/SMAD2 signaling.
Treatment with ACVR2B-Fc reduces apoptosis
and optimizes cardiomyocyte energy meta-
bolism in hypoxic conditions.
In addition to BMPs,28,29 myostatin and acti-
vin A are potent regulators of muscle growth.30
Myostatin is predominantly expressed in the
skeletal muscle but also to lower extent in
the heart. Myostatin is an important negative
regulator of muscle growth, as evidenced bymassive skeletal muscle hypertrophy in myostatin knockout
mice.31 Constitutive myostatin knockout induces myofiber hyper-
trophy and hyperplasia during development and32 results in down-
regulation of genes encoding slow isoforms of contractile proteins
and genes encoding proteins involved in energy metabolism.33 We
also detected expression of these genes modified in our ACVR2B-
Fc-treated IR hearts. In contrast, earlier studies with post-develop-
mental reduction of myostatin expression by Cre-lox recombina-
tion or by ACVR2B-Fc resulted in hypertrophy, but not to the
downregulation of genes encoding slow isoforms of skeletal musclelecular Therapy Vol. 27 No 3 March 2019 605
Figure 5. ACVR2B-Fc Improves LV Function under
Prolonged Cardiac Stress
(A) Mice were treated with anthracycline doxorubicin for
2-week period, which induces cardiotoxicity. Mice were
treated simultaneously with vehicle or ACVR2B-Fc for
2 weeks and LV tissue was analyzed with high-resolution
respirometer. ACVR2B-Fc improved cardiac respiration
in doxorubin-stressed hearts. Right panel represents
respiration capacity for the whole heart. CI, complex I; CII,
complex II; ETS, electron transfer system (maximal un-
coupled respiration). n = 7. (B) ACVR2B-Fc also slightly
improved citrate synthase activity. n = 7. (C) As analyzed
with echocardiography, ACVR2B-Fc preserved cardiac
systolic function in cumulative doxorubicin-induced
toxicity at 4 weeks. n = 9, 6, 9. Full echo data in Table S4.
(D) As analyzed with qPCR from LV at 4 weeks, ACVR2B-
Fc reduced doxorubicin-induced upregulation of natri-
uretic peptides ANP (Nppa) and BNP (Nppb). n = 9, 7, 8.
Data are presented as mean ± SD. *p < 0.05, **p < 0.01.
Molecular Therapycontractile proteins or genes encoding proteins involved in energy
metabolism.34,35
Activins mainly reside in gonadal tissue and regulate reproduction by
stimulating FSH release from the pituitary gland. In addition, activin
A is expressed in the skeletal muscle and the heart and regulates
essential biological functions, such as cell proliferation and differen-
tiation, immune response, and angiogenesis.5 Similarly to myostatin,
activin A negatively and prominently regulates muscle growth.9,30 In
a recent study in zebrafish, activin A and myostatin were shown to
have opposite effects on cardiac repair after cryoinjury: activin A
led to accelerated recovery, whereas myostatin hindered the regener-
ation process. Furthermore, myostatin was suggested to bind
predominantly to ACVR2B and activate SMAD2, while activin A
was suggested to bind to ACVR2A and promote activation of
SMAD3.36 This is in line with our findings showing that myostatin
exacerbates ischemic injury and ACVR2B-Fc blocks the activation
of myostatin-activated SMAD2. However, our data does not allow
us to determine to which extent the ACVR2B-Fc-mediated cardio-
protection stems from inhibition of canonical SMAD2 pathway or in-
hibition of non-canonical JNK pathway. SMAD2/3 controls genes
regulating hypertrophy and atrophy, even apoptosis. JNK can also
regulate hypertrophy, metabolism, and mitochondria-mediated cell
death in response to oxidative stress.37 JNK can even interact with
SMAD2 pathway in regulation of muscle remodeling.38 Apparently,
the anti-apoptotic effect of ACVR2B-Fc is mediated by inhibition
of JNK activity but occurs in cross-talk with other signaling pathways,
including SMAD2.
BMPs have been shown to contribute to ischemic injury,39 but we did
not detect immediate BMP activation in cardiomyocytes in response
to hypoxia by measuring BRE-luc promoter activity. Fstl1, inhibiting
BMPs and their signaling via the SMAD1/5/8 pathway, has been
shown to reduce IR injury by reduction of apoptosis and inflamma-
tory response.40,41 In a recent study, Fstl1 was also shown to alter606 Molecular Therapy Vol. 27 No 3 March 2019energy substrate metabolism and increase oxidative respiration in
the heart.42 It remains to be shown how BMP and GDF pathways,
via SMAD1/5/8 and SMAD2/3, respectively, or via noncanonical
pathways, overlap in their contribution to IR injury.
GDF11, although a close homolog to myostatin, has versatile effects
partly divergent from myostatin. Myostatin predominantly affects
muscle mass, while the ablation of GDF11 results in defects in skeletal
patterning during embryogenesis, resulting in perinatal lethality.43,44
Unlike myostatin, GDF11 also participates in erythropoiesis in adult.
GDF11 was formerly considered as a rejuvenation factor, and resto-
ration of levels of GDF11 were shown to provide protection from
age-related pathological cardiac hypertrophy.45 In subsequent
studies, aging was not associated with a decrease in circulating
GDF11 levels,46 and elevation of GDF11 did not provide therapeutic
effect for cardiac hypertrophy.47 In skeletal muscle, GDF11 expres-
sion was even shown to increase during aging and inhibit muscle
regeneration, similar to inhibitory effects of myostatin.48 Inducing
supraphysiological levels of GDF11 led to both skeletal and cardiac
muscle atrophy, while myostatin reduced only skeletal muscle
growth.49 We detected upregulation of cardiac myostatin and activin
A expression immediately after ischemia, while expression of GDF11
was upregulated at a later phase. This is of interest since GDF11 was
recently shown to reduce cardiac remodeling after IR injury.50
Our results thus confirm that myostatin and its close homolog GDF11
are differently expressed in the heart in response to ischemia and indi-
cate that they may participate in different processes. Furthermore,
GDF11 did not affect cardiomyocyte survival in acute hypoxia, while
administration of myostatin exacerbated cardiomyocyte death.
This suggests that, blocking the effects of GDF11 as a bystander,
ACVR2B-Fc does not exacerbate myocardial ischemic injury. We
cannot fully rule out that additionally, blockade of GDF11 could
partly contribute to benefits of ACVR2B-Fc in IR. GDF11 is known
to negatively affect erythrocyte maturation,7 and its blockade by
www.moleculartherapy.orgACVR2B-Fc increases extramedullary hematopoiesis leading to
splenomegaly.30 When performing erythrocyte count 24 h post-MI,
we found short-term treatment with ACVR2B-Fc did not increase
the number of erythrocytes, excluding increased red blood cell avail-
ability as a possible benefit during IR.
ACVR2B-FcContributes to Ischemia Protection byRegulation of
Catabolic Pathways and Hypertrophy
In the present study, administration of ACVR2B-Fc rapidly induced
cardiomyocyte growth. This was not accompanied by downregulation
of atrogenes or induction of Akt, although GSK3b phosphorylation
was transiently increased. In a previous study using our ACVR2B-
Fc, blocking ACVR2B ligands did not increase protein synthesis in
the healthy heart as it does in the skeletal muscle.20 Here, administra-
tion of ACVR2B-Fc reduced lipidated LC3, a marker of autophagy, in
the heart, suggesting that decreased autophagy may be a mechanism
of increased cardiomyocyte size by ACVR2B-Fc. The administration
of ACVR2B-Fc has also reduced LC3 lipidation in skeletal muscle,19
which probably occurs through blocking of myostatin, as myostatin
can induce autophagy.51 It is also possible that ACVR2B-Fc-induced
higher glucose concentration or uptake contributed to increased
hypertrophy, especially under apparent sympathetic stimulus.52
CITED4 overexpression in cardiomyocytes was recently shown to
be sufficient for the induction of cardiac hypertrophy and reduction
of autophagy, reduced adverse cardiac remodeling, and reduced
fibrosis after ischemic injury.24 Interestingly, we detected rapid induc-
tion of cardiomyocyte hypertrophy by ACVR2B-Fc in IR hearts,
which was accompanied by upregulation of CITED4.
ACVR2B-FcContributes to Ischemia Protection byRegulation of
Cardiomyocyte Metabolism
Approaches to alleviate IR injury aim at pharmaceutical compounds
that reduce fatty acid uptake into mitochondria, inhibit mitochon-
drial fatty acid oxidation, or increase glucose oxidation.53 Blocking
myostatin signaling in the heart by genetically inactivating myostatin
from cardiomyocytes results in enhanced glycolysis, augmented
glycogen storage, and cardiac hypertrophy in adult mice.54 In that
study, however, myostatin deletion led to LV dilatation, impaired car-
diac function, and increased mortality in otherwise healthy mice.54
Authors of the study showed this metabolic switch leading to cardiac
hypertrophy to be mediated by AMPK activation. Similarly, we found
AMPK target acetyl CoA carboxylase to be phosphorylated by
myostatin inhibition by ACVR2B-Fc in healthy hearts. Phosphoryla-
tion of acetyl CoA carboxylase downregulates fatty acid synthesis.55
However, we did not detect an increase in acetyl CoA carboxylase
phosphorylation in IR hearts, suggesting that in contrast to healthy
hearts, ACVR2B-Fc did not affect fatty acid synthesis in ischemic
hearts.
Upregulation of PGC1a results in increased mitochondrial biogenesis
and oxidative phosphorylation.56 PGC1a4 isoform that results from
alternative promoter usage and splicing of the primary PGC1a tran-
script induces robust skeletal muscle hypertrophy without producing
a metabolic phenotype similar to what PGC1a1 isoform produces.57In our study, upregulation of PGC1a1 and PGC1a4 isoforms by
ACVR2B-Fc (together with inhibition of GSK3b) at least partly
explain the increased hypertrophy but may represent compensatory
response to metabolic changes in the heart. Inhibition of myostatin
signaling has also been shown to have beneficial metabolic effects
in obesity and diabetes, including enhanced glucose tolerance,
improved brown adipogenesis, and reduced fat mass.7,58
Our data shows that ACVR2B-Fc treatment reduced metabolic activ-
ity in adult mouse cardiomyocytes after IR, reducing oxygen con-
sumption. This resembles the phenomenon known as myocardial
hibernation, in which the heart downregulates metabolism in order
to adapt to ischemic conditions.59 At reperfusion, this may reduce
the burst of reactive oxygen species and calcium overload in cardio-
myocytes, and this approach has actually been suggested as a possible
therapy for reperfusion injury. Basheer et al.60 recently demonstrated
a similar cardioprotective phenotype in ischemic injury with pretreat-
ment of mice with adenoviral infection of a mitochondrial targeting
factor. The approach mimicked the cardioprotective effect of
ischemic preconditioning by inducing metabolic quiescence and
limiting production of damaging levels of reactive oxygen species in
the mitochondria. Our results suggest ACVR2B-Fc may promote
entering of the cardiomyocytes to an adaptive hibernating state that
reduces energy substrate utilization and oxygen demand to match
the oxygen availability in IR.
Finally, we determined whether the acute cardioprotective effect and
metabolic changes induced by ACVR2B-Fc could provide beneficial
effects on cardiac function after prolonged cardiac stress. Efficacy
of ACVR2B-Fc on mitochondria function was determined in a
cardiotoxicity model, as doxorubicin is known to alter cardiac meta-
bolism.25 Besides the disruption of mitochondrial oxidative respira-
tion, which includes inhibition of complex I activity, many other
proteins in metabolic pathways, such as mitochondrial creatine
kinases, are affected by doxorubicin.25 We found that treatment
of mice with ACVR2B-Fc improved mitochondrial function and
prevented the deterioration of cardiac systolic function in doxoru-
bicin-treated mice. This suggests that, in addition to its acute pro-
survival and metabolic effects in IR injury, ACVR2B-Fc has more
broad beneficial effects on the heart.
Cardiac Preconditioning by ACVR2B-Fc Is Required for Full
Cardioprotection
Activin A and mature myostatin reside in a latent complex extracel-
lularly, ready to bind ACVR2B when released from their binding pep-
tides. Activin and myostatin activities are endogenously inhibited by
follistatin or follistatin-like proteins or, in case of myostatin, by GDF-
associated serum proteins that bind to ligands and neutralize their ef-
fects. Activins are also inhibited by inhibins that interfere ACVR2A/
ACVR2B binding to type I receptors and activation of intracellular
signal transduction cascades such as SMAD2/3.
We chose to study ACVR2B-Fc as a therapeutical approach due to
its benefits in hypertrophic muscle growth and its broader ligandMolecular Therapy Vol. 27 No 3 March 2019 607
Molecular Therapyspecificity. ACVR2B-Fc blocks signaling of myostatin, its close ho-
molog GDF11, as well as activin A, activin B, and BMP10.2 Inhibi-
tion of myostatin signaling by ACVR2B-Fc has been studied
in muscle-wasting conditions. Myostatin signaling blockade has
been achieved by specific antibodies,61 by antibodies targeted to
ACVR2,62 ligand traps including ACVR2B-Fc,18–20,63,64 or by over-
expression of natural inhibitors such as follistatin.40,42 However,
myostatin and other TGF-b family members, especially GDF11
and activin A, share a high degree of similarity in receptor
recognition sites thus lacking target specificity. Recently, human
monoclonal antibodies to pro-myostatin and pro-GDF11 were
developed.65 These inhibit their targets by blocking growth factor
release from the prodomain and work with higher specificity, since
pro-domains are much less conserved than mature domains. It re-
mains to be shown whether pro-domain targeting approach, which
reduced glucocorticoid-induced muscle wasting,65 could also work
in protection from IR injury and whether it offers extra benefits
when inhibiting myostatin specifically.
To conclude, the changes described in this study, which improve car-
diomyocyte response to hypoxia, predominantly require ACVR2B-
Fc to be administered prior to IR. Although administration of
ACVR2B-Fc at reperfusion inhibits canonical SMAD2/3 and
non-canonical pathways, this is sufficient to only partially inhibit
pathological pathways. Therefore, transcriptional modification
toward metabolically optimized cardiac function is needed to
achieve full cardioprotective effect of ACVR2B-Fc. Our findings
resemble ischemic preconditioning, which is known to protect
the heart from IR injury and is associated with priming of mito-
chondria into a metabolically altered stress-resistant state. Accord-
ing to our results, systemic blockade of ACVR2B ligands was suffi-
cient to promote protection from IR in the heart. In addition to
ACVR2B, myostatin and activin A also signal through ACVR2A re-
ceptors. In a recent study, dual blockade of ACVR2A/ACVR2B by
bimagrumab was shown to be required for full anabolic response
in skeletal muscle.3 It remains to be shown whether dual blockade
of ACVR2 receptors could offer extra benefit in treatment of IR
injury.
MATERIALS AND METHODS
An expanded methods section is provided in the Supplemental Infor-
mation. Experimental protocols were approved by the Animal Use
and Care Committee of the University of Oulu and the national An-
imal Experiment Board of Finland. 8- to 10-week-old male C57BL/6J
mice were anaesthetized with isoflurane and subjected to IR by liga-
tion of the left anterior descending coronary artery (LAD) for
30 min, after which the slip knot was released, allowing reperfusion
of the ischemic myocardium for 6 or 24 h, as previously described.66
The experimental timeline is depicted in Figure S1. ACVR2B-Fc re-
combinant fusion protein18 was administered as 10 mg/kg subcutane-
ously (s.c.) 24 h prior to IR and at reperfusion (termed “ACVR2B-Fc
pretreatment”) or only at reperfusion (termed “ACVR2B-Fc at reper-
fusion”). Data are expressed as mean ± SD. *p < 0.05, **p < 0.01 and
***p < 0.001.608 Molecular Therapy Vol. 27 No 3 March 2019SUPPLEMENTAL INFORMATION
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